<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124028</url>
  </required_header>
  <id_info>
    <org_study_id>ZXH-ITP2021</org_study_id>
    <nct_id>NCT05124028</nct_id>
  </id_info>
  <brief_title>A Study of Orelabrutinib in Patients With ITP</brief_title>
  <official_title>A Study of Orelabrutinib in Patients With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project was undertaken to evaluate the efficacy and safety of BTK inhibitor&#xD;
      Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia&#xD;
      (ITP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a prospective trial of 10 adults with ITP in China.&#xD;
      Orelabrutinib is administered as 50 mg po. qd for 6 weeks. Platelet count, bleeding and other&#xD;
      symptoms were evaluated before and after treatment. Adverse events are also recorded&#xD;
      throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response (OR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The maintenance of platelet count ≥ 30 x 10^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-week follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Complete response (CR) was defined as platelet count more than 100,000 per cubic millimeter and absence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>6 weeks</time_frame>
    <description>The time from starting treatment to time of achievement of Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>6 weeks</time_frame>
    <description>The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>Potential side effects include leukopenia, nausea and diarrhea, infectious diseases, etc .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Orelabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orelabrutinib 50mg po qd 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib</intervention_name>
    <description>50mg po qd 6 weeks</description>
    <arm_group_label>Orelabrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed primary refractory ITP&#xD;
&#xD;
          -  Platelet counts &lt;30×10^9/L or with bleeding symptoms&#xD;
&#xD;
          -  Willing and able to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary thrombocytopenia&#xD;
&#xD;
          -  Received chemotherapy or anticoagulants or other drugs affecting the platelet counts&#xD;
             within 6 months before the screening visit&#xD;
&#xD;
          -  HIV infection or hepatitis B virus or hepatitis C virus infections&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Severe medical condition (e.g., unstable angina, congestive heart failure,&#xD;
             uncontrolled hypertension or cardiac arrhythmia)&#xD;
&#xD;
          -  Nursing or pregnant patients&#xD;
&#xD;
          -  Patients who are deemed unsuitable for the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Hui Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Hui Zhang, MD</last_name>
    <phone>010-88324577</phone>
    <email>zhangxh100@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiao-Hui Zhang, MD</last_name>
      <phone>+86 13522338836</phone>
      <email>zhangxh100@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Hui Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Bruton's Tyrosine Kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

